Atria Investments Inc Sells 1,309 Shares of Smith & Nephew plc (NYSE:SNN)

Atria Investments Inc lessened its stake in shares of Smith & Nephew plc (NYSE:SNN) by 5.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,665 shares of the medical equipment provider’s stock after selling 1,309 shares during the period. Atria Investments Inc’s holdings in Smith & Nephew were worth $675,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of SNN. Mather Group LLC. raised its stake in shares of Smith & Nephew by 9,735.3% during the second quarter. Mather Group LLC. now owns 1,672 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 1,655 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Smith & Nephew by 1,894.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 1,648 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Smith & Nephew by 92.5% in the second quarter. EverSource Wealth Advisors LLC now owns 2,454 shares of the medical equipment provider’s stock worth $61,000 after buying an additional 1,179 shares in the last quarter. GAMMA Investing LLC raised its stake in Smith & Nephew by 160.0% in the third quarter. GAMMA Investing LLC now owns 2,257 shares of the medical equipment provider’s stock worth $70,000 after buying an additional 1,389 shares in the last quarter. Finally, Opal Wealth Advisors LLC bought a new position in Smith & Nephew in the second quarter worth approximately $101,000. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew Price Performance

NYSE SNN opened at $25.51 on Wednesday. The firm’s fifty day simple moving average is $28.49 and its two-hundred day simple moving average is $27.89. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. Smith & Nephew plc has a 12-month low of $23.65 and a 12-month high of $31.72.

Analysts Set New Price Targets

A number of brokerages recently commented on SNN. Berenberg Bank downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.